Spots Global Cancer Trial Database for Study of Pazopanib Monotherapy in Patients With Unresectable, Metastatic Neuroendocrine Tumor
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study of Pazopanib Monotherapy in Patients With Unresectable, Metastatic Neuroendocrine Tumor
Official Title: Phase II Study of Pazopanib Monotherapy in Patients With Unresectable, Metastatic Neuroendocrine Tumor
Study ID: NCT01099540
Conditions
Interventions
Study Description
Brief Summary: To determine the response rate of pazopanib when administered as monotherapy in patients with unresectable neuroendocrine tumor.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Samsung Cancer Center, Seoul, , Korea, Republic of
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
